Doyu Kim

Doyu Kim

Auto-generated profile, based on publicly available information

Doyu Kim

Department of Nuclear Medicine, Incheon St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
HJHyeonseok Jeong
Hyeonseok Jeong
DKDoyu Kim
Doyu Kim
SNSeunghee Na
Seunghee Na
BKByung Seok Kim
Byung Seok Kim
JOJin Kyoung Oh
Jin Kyoung Oh
ISIn-Uk Song
In-Uk Song
Background: Low-intensity focused ultrasound (LIFU), a non-invasive targeted brain stimulation technology, has shown promise for therapeutic applications in Alzheimer's disease (AD) patients. Despite its potential, the implications of repeated LIFU neuromodulation in AD patients remain to be investigated. Objective: This pilot study evaluated the safety and potential to improve cognition and functional connectivity following repeated LIFU treatment in AD patients. Methods: Ten early-stage AD patients underwent six sessions of neuronavigation-guided LIFU targeting the left dorsolateral prefrontal cortex (DLPFC) within 2–3 weeks, alongside ongoing standard pharmacotherapy. Neuropsychological assessments and resting-state functional magnetic resonance imaging were performed at baseline and eight weeks post-treatment. Results: Memory performance (p = 0.02) and functional connectivity between the left DLPFC and both the left perirhinal cortex and left dorsomedial prefrontal cortex (corrected p < 0.05) significantly improved from baseline. Additionally, enhancements in memory performance were positively correlated with increases in functional connectivity of the left DLPFC with the left perirhinal cortex (Kendall's tau = 0.56, p = 0.03). No adverse events were reported during the LIFU treatments or at the subsequent follow-up. Conclusions: LIFU may have the therapeutic potential to enhance both brain network connectivity and memory functions in AD patients. Our results provide a basis for further research, including randomized sham-controlled trials and optimization of stimulation protocols, on LIFU as a supplementary or alternative treatment option for AD. Trial registration: Clinical Research Information Service, KCT0008169, Registered on 10 February 2023